Dose of Labeled Cholesterol for Kinetics: A Pilot Study

N/ACompletedNCT02065817

Mayo Clinic7 enrolled

Overview

This is a pilot study to determine the optimum time and dose to draw blood samples using a tracer for HDL kinetics.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Lipid Metabolism

Interventions

stable isotope of cholesterolOTHER

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: • Healthy men and women ages 18 - 50 Exclusion Criteria: * Cardiovascular disease * Metabolic disease * Hematologic disorder * Liver or kidney disease * phenylketonuria * Currently taking lipid lowering medications or any other drugs that could affect lipid metabolism

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

Incorporation of orally administered 13C3 cholesterol into plasma cholesterol

13C3 cholesterol, which is labeled with a stable isotope, will be administered orally. Blood samples will be taken every 4-6 hours for 72 hours for the measurement of stable isotopic enrichment in cholesterol using gas chromatography-mass spectrometry. The study has a dual purpose: to determine the optimum oral dose of isotope, and to determine the time of peak enrichment in plasma cholesterol.

Time frame: 72 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.